Emerging Business Models in the Pharmaceutical Industries ...

15%
Percentage Revenues by Segment
5%
80%
Source: Company’s Annual Reports
Pharmaceuticals
Consumer Healthcare
Animal Health
Strategic Direction
Wyeth is focussing on acquiring small players
with sound R&D facilities and supporting them
with their marketing infrastructure.
To boost its biotechnology initiatives, in January
2004 Wyeth has purchased Ingenuity Pathways
Analysis for use across the entire drug
discovery and development chain from early
discovery to clinical phases. Ingenuity delivers
systems biology expertise to biologists and
bioinformaticians through pathways analysis
software, genome-scale computable network
databases, and knowledge management
12
10
8
6
4
2
0
Wyeth
Revenues by Geographic Segments (billion US$)
US UK Other International
Source: Company’s Annual Reports
Strategic Analysis of the Pharma Market, Future Revenue Models and Key Players 72
2001
2002
2003
services and infrastructure, resulting in increased productivity and faster
drugs to market. In the area of genomic research Wyeth has partnered
with Genome Therapeutics Corp, Waltham, Mass, utilising genomics for
the discovery of new therapeutic agents. The company uses the DTC
channel to market its branded drug Premarin Tabs.
In the area of integrated research Wyeth has partnered with ArQule, Inc.,
a chemistry company committed to accelerating drug discovery by using
techniques to design and produce the molecules to be used in future
medicines.
The company has also entered into research collaboration with
Cambridge Antibody Technology Group plc, which is dedicated to
antibody development.